Kenvue Shares Plunge Amid Speculation of RFK Jr. Linking Tylenol to Autism

Kenvue Inc. saw a sharp decline in its share price following a Wall Street Journal report indicating that Health and Human Services Secretary Robert F. Kennedy Jr. is likely to connect the company’s Tylenol painkiller to autism. While the agency has labeled the report as “speculation,” the news has already impacted investor confidence.

The federal government is anticipated to release its comprehensive findings on autism later this month. Citing individuals familiar with the matter, the Journal reported on Friday that the forthcoming findings are expected to suggest a potential link between the use of over-the-counter pain medication containing acetaminophen, the primary ingredient in Tylenol, and autism. The market is closely monitoring this developing situation as Kenvue faces significant scrutiny.

阅读中文版 (Read Chinese Version)

Disclaimer: This content is aggregated from public sources online. Please verify information independently. If you believe your rights have been infringed, contact us for removal.